Clarifying the controversial risk-benefit profile of soluble ACE2 in COVID-19
10.1186/s13054-020-03097-w
Saved in:
Main Author: | Leow M.K.S. |
---|---|
Other Authors: | DUKE-NUS MEDICAL SCHOOL |
Format: | Letter |
Published: |
BioMed Central
2020
|
Online Access: | https://scholarbank.nus.edu.sg/handle/10635/177325 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
Similar Items
-
The ACE-2 in COVID-19 : foe or friend?
by: Dalan, Rinkoo, et al.
Published: (2021) -
Controversial endocrine interventions for the aged
by: Leow M.K.S., et al.
Published: (2020) -
Modeling IS planning benefits using ACE
by: Ang, J.S.K., et al.
Published: (2013) -
Asking clarifying questions: to benefit or to disturb users in web search?
by: Zou, Jie, et al.
Published: (2023) -
Genetic polymorphisms of ACE1, ACE2, and TMPRSS2 associated with COVID-19 severity: A systematic review with meta-analysis
by: Wacharapol Saengsiwaritt, et al.
Published: (2022)